What is Leerink Partnrs' Forecast for SLDB Q1 Earnings?

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Solid Biosciences in a research report issued on Monday, April 21st. Leerink Partnrs analyst J. Schwartz forecasts that the company will post earnings of ($0.41) per share for the quarter. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences' Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS and FY2026 earnings at ($1.94) EPS.

A number of other brokerages have also recently issued reports on SLDB. Chardan Capital reissued a "buy" rating and issued a $16.00 target price on shares of Solid Biosciences in a report on Friday, March 7th. HC Wainwright upped their price objective on Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. JPMorgan Chase & Co. cut their target price on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research note on Thursday, March 13th. Finally, Truist Financial initiated coverage on shares of Solid Biosciences in a research report on Wednesday, January 8th. They set a "buy" rating and a $16.00 price target for the company. Eight analysts have rated the stock with a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $15.67.

Solid Biosciences Stock Performance

Shares of Solid Biosciences stock traded down $0.07 during trading hours on Thursday, reaching $3.23. The company's stock had a trading volume of 675,190 shares, compared to its average volume of 935,526. Solid Biosciences has a one year low of $2.45 and a one year high of $10.99. The company's 50 day simple moving average is $4.24 and its 200 day simple moving average is $4.50. The stock has a market cap of $250.30 million, a P/E ratio of -1.06 and a beta of 2.07.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its position in Solid Biosciences by 4.0% in the fourth quarter. Wellington Management Group LLP now owns 124,551 shares of the company's stock worth $498,000 after purchasing an additional 4,747 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Solid Biosciences by 1.8% in the fourth quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company's stock valued at $11,400,000 after buying an additional 50,000 shares during the period. Redmile Group LLC acquired a new stake in shares of Solid Biosciences in the fourth quarter valued at $2,461,000. D. E. Shaw & Co. Inc. bought a new position in Solid Biosciences during the fourth quarter valued at about $208,000. Finally, Corton Capital Inc. acquired a new position in Solid Biosciences during the fourth quarter worth about $41,000. 81.46% of the stock is currently owned by institutional investors.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.